Efficacy and Safety of Tofogliflozin on 24-H Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium–Glucose Cotransporter 2 Inhibitor

Akira Kurozumi,Yosuke Okada,Mototsugu Shimokawa,Yukiko Goshima,Takashi Otsuka,Manabu Narisawa,Keiichi Torimoto,Yoshiya Tanaka

Efficacy and Safety of Tofogliflozin on 24-H Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium–Glucose Cotransporter 2 Inhibitor

2019

Akira Kurozumi
Yosuke Okada
Mototsugu Shimokawa
Yukiko Goshima
Takashi Otsuka
Manabu Narisawa
Keiichi Torimoto
Yoshiya Tanaka

Abstract Background: To compare the impact of two sodium–glucose cotransporter 2 (SGLT2) inhibitors, tofogliflozin and ipragliflozin, on hypoglycemia in patients with type 2 diabetes mellitus (T2DM...

Keywords:

Internal medicine
Crossover study
Sodium-Glucose Cotransporter 2 Inhibitor
Endocrinology
Diabetes mellitus
Medicine
Tofogliflozin
SGLT2 Inhibitor
Cotransporter
Type 2 Diabetes Mellitus
Hypoglycemia
Type 2 diabetes
Ipragliflozin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations